Eli Lilly has had success in its Phase III trial for necitumumab, the company’s successor to Erbitux.
The study produced promising overall survival data for non-small cell lung cancer which means that a regulatory filing has been slated for 2014. The drug, when combined with others, allowed for a much better survival rate when compared to chemotherapy alone for people with stage IV metastatic squamous non-small cell lung cancer.
The results were a surprise, coming off the back of fears that the drug caused blood clots in some patients. However, instances have become less frequent. If approved, necitumumab may become the first drug to treat squamous lung cancer.